DSM-Firmenich AG (KDSKF) Q1 2025 Earnings Call Transcript

2025-05-02 15:55:19 ET

DSM-Firmenich AG (KDSKF)

Q1 2025 Results Conference Call

April 30, 2025 3:00 AM ET

Company Participants

Dave Huizing - Head of Investor Relations

Ralf Schmeitz - Chief Financial Officer

Conference Call Participants

Lisa De Neve - Morgan Stanley

Alex Sloane - Barclays

Nicola Tang - BNP Paribas

Chetan Udeshi - JPMorgan

Charles Eden - UBS

Matthew Yates - Bank of America

Sebastian Bray - Berenberg

Martin Roediger - Kepler Cheuvreux

Presentation

Dave Huizing

Good morning, and thank you for joining today's call. I'm sitting here with Ralf Schmeitz, our CFO. This morning, we published our first quarter 2025 trading update together with a presentation to investors, which you can find on our website.

Here, you can also find our disclaimers about forward-looking statements. Following Ralf's opening comments, we will open the line for questions. Importantly, and as a reminder, sell-side analysts who want to ask questions will need to register via the link, which they can find on our website in the financial calendar. If you have not done so yet, you can still switch now. And with that, Ralf, please go ahead.

Ralf Schmeitz

Well, thanks, Dave, and good morning. Good morning from a sunny, so at least sun is shining and happy that it's coupled with today. We'll take you through our quarter one results and a few of the strategic updates along the way as well, and we'll zoom in into the business units as usual. But let me start with the overall picture and framing of our performance to date. We started the year in a good way.

Overall, you see already a couple of numbers on this slide. Overall, 8% organic growth, very encouraging start of the year. And obviously, that translated into a very nice step-up in profitability. We've seen a 40% step-up in EBITDA and a margin of 20%. And we'll come back with some more detail, both for the group and the BUs in a little while. So bear with me on that. But very pleased with that start of the year.

On the strategic side, we also made good progress at the full year results. We already talked about the sale to Novonesis of the Feed Enzymes business. We're well underway in completing that. We're waiting on the final goal of two smaller jurisdictions. So confident that that will close into the second quarter.

Reminder, we sold the business for EUR1.5 billion, which will translate into a net cash of somewhat above EUR1.4 billion and will obviously drive a substantial book profit as well. We'll communicate that upon closing of the transaction....

Read the full article on Seeking Alpha

For further details see: